Paper Details

  1. Home
  2. Paper Details

Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression.

Author: FriedeTim, NicholasRichard, RöverChristian, StraubeSebastian

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Reviews of research on multiple sclerosis (MS) treatments found that the rate of relapses in placebo groups has decreased over the past 20 years. This may be due to improvements in treatment and the "regression to the mean" effect, where initial measurements are unusually high, and later measurements tend to be closer to the average. The study aims to determine if a similar trend is seen in the progression of disability, measured using the EDSS scale.
Paper Details　
Original Abstract of the Article :
Recent systematic reviews of randomised controlled trials (RCTs) in relapsing multiple sclerosis (RMS) revealed a decrease in placebo annualized relapse rates (ARR) over the past two decades. Furthermore, regression to the mean effects were observed in ARR and MRI lesion counts. It is unclear whethe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556534/

データ提供：米国国立医学図書館（NLM）

EDSS Progression in Relapsing MS: A Shifting Landscape

Multiple sclerosis (MS) is a complex neurological disorder that can significantly impact an individual's life. The Expanded Disability Status Scale (EDSS) is a widely used tool for assessing disability progression in MS. This study, through a systematic review and meta-regression, explores the patterns of EDSS progression in placebo cohorts of patients with relapsing MS. The authors analyze data from randomized controlled trials, looking for trends in EDSS scores and considering the impact of factors like regression to the mean.

A Closer Look at EDSS Progression in Relapsing MS

The study reveals some intriguing findings. While previous research has observed a decline in relapse rates in placebo cohorts over time, the authors found that EDSS progression does not exhibit a similar pattern. This suggests that EDSS progression might not be solely driven by relapses and may involve other contributing factors. This study underscores the complexity of MS and the need for further investigation into the multifaceted nature of disease progression.

Navigating the Uncertainties of MS

This study reminds us that MS is a dynamic and unpredictable disease. The study's findings challenge our understanding of EDSS progression, highlighting the need for a more comprehensive approach to assessing disability in MS. While it's important to be mindful of potential relapses, the study emphasizes the importance of monitoring for other factors that could influence EDSS scores and ultimately impact a patient's quality of life.

Dr. Camel's Conclusion

Like a shifting desert landscape, EDSS progression in relapsing MS can be unpredictable. This research provides valuable insights into the nuances of EDSS progression, highlighting the need for a holistic approach to managing this complex disorder.

Date :
  1. Date Completed 2016-05-18
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

26327532

DOI: Digital Object Identifier

PMC4556534

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.